Psychedelics biotech Eleusis has its eyes on an expansion, and it’s going the SPAC route to get it. The biotech announced earlier today that it’s teaming up with a SPAC born out of asset manager Silver Spike Capital to make Eleusis a public company. Once the deal goes through sometime
Continue readingPsychedelics company Eleusis to go public through SPAC Silver Spike Acquisition Corp. II
Psychedelics sciences firm Eleusis plans to go public through a deal with SPAC Spike Acquisition Corp. II (SPKB) in a deal that give the combined company an enterprise value of $446M
Continue readingPsychedelics Are The Hot Conference Topic
It wasn’t that long ago when psychedelics emerged as a potentially better natural plant-based medicine for treating such things as treatment-resistant depression (TRD), into what is now a billion-dollar juggernaut of an industry. Then an even curiouser thing happened. Around 2015, organizers of more and more conferences about cannabis—and some that were not about cannabis […]
Continue readingPsychedelics Firm Eleusis Goes Public Via Merger With Silver Spike Acquisition Creating $450M Company | Benzinga
British psychedelics company Eleusis will go public via a merger with Silver Spike Acquisition Corp. II (“S…
Continue readingPsychedelics & MDMA are finally being legalised for mental health therapy
One psychologist called it “the greatest leap forward in mental health care since the invention of psychotherapy.”
Continue readingHow 2021 became the year of psychedelics – and why 2022 is set to be even bigger
It’s no secret that psychedelics are on the comeback trail, with a record number of trials and total investment in the hundreds of millions of dollars in
Continue readingHow 2021 became the year of psychedelics – and why 2022 is set to be even bigger
As the psychedelics industry is set to have another record-breaking year, we take a look at the milestones of 2021 and what we can expect in the coming year.
Continue readingEleusis joins cooled-off SPAC market with $288M to bankroll psychedelic-based depression drug
With investor interest in psychedelics heating up, Eleusis joins the relatively quiet SPAC market in a deal that gives the biotech $288 million to test a psilocybin-based treatment for depression. The proceeds will also bankroll an expansion of subsidiary Andala’s drug therapy clinics.
Continue readingSeattle and Detroit Move Toward Decriminalizing Psychedelics – Capitol Hill Times
Seattle and Detroit approved this fall measures to protect consumers of “entheogenic” plants and fungi. These policies form part of a larger trend, which began […]
Continue readingBill could open the door to legalize medical-use psychedelics in Utah
Rep. Brady Brammer acknowledges he’s not the type to run legislation on psychedelics.
Continue reading